Acute mountain sickness Injury, Occupational Diseases, Poisoning Mountain sickness
Conditions
Interventions
Treatment group one: gabapentin 600 mg orally
single dose within first two hours of ascent.
Treatment group two: mono-hydrate lactose (same shape and weight to gabapentin capsules)
single dose within first two hours of ascent.
Sponsors
Tehran University of Medical Sciences (Iran)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age of 15 to 65 years 2. Ascent to a high altitude of 3500 to 3900 metres above sea level from an altitude of at least 1500 metres using cable cars (within 45 to 90 minutes) 3. Consenting participant 4. May reasonably be expected to complete a 24 hour trial
Exclusion criteria
Exclusion criteria: 1. Severe cardiac, pulmonary, or liver disease 2. Severely impaired kidney function 3. Current history of alcohol or drug abuse 4. Pregnancy 4. Known allergy to gabapentin 5. Treatment with anticonvulsants or tricyclic antidepressants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. AMS incidence (Lake Louise acute mountain sickness score of equal or more than three with headache and at least one other symptom) 2. AMS severity (score of five or more) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Duration of high-altitude headache free phase after prophylaxis initiation 2. Duration of moderate to severe high-altitude headache free phase after prophylaxis | — |
Countries
Iran
Outcome results
None listed